Trials
4 active
4 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Recombinant humanized anti-GPRC5D/BCMA/CD3 trispecific antibody injection”In the company’s words, NCT07764861 on ClinicalTrials.gov
- Tested for
- Multiple Myeloma (3 trials), Relapsed or Refractory Multiple Myeloma
- Main trialPhase 3
- “The purpose of this study is to evaluate how well IBI3003 works when compared with the investigator's choice regimen (DPd or PVd or SVd)”In the company’s words, NCT07623798 on ClinicalTrials.gov
- Other names
- trispecific antibody
Other drugs for Multiple Myeloma
- MezigdomideCelgene · Phase 3
- Anitocabtagene-autoleucelGilead (Kite) · Phase 3
- CM336Keymed Biosciences Co.Ltd · Phase 3
- PomalidomideCelgene · Phase 3
- CevostamabRoche · Phase 3
- DaratumumabJanssen Research & Development, LLC · Phase 3
Coming up3
- 31 DecPhase 2 trial completes · ClinicalTrials.gov
- 30 Jun 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 31 May 2029Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 31 May 2029 | A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 | |
| Phase 2Not yet recruiting | 31 Dec 2026 | A Open-Label Phase in Participants With Multiple Myeloma | |
| Phase 1/2Recruiting | 31 Oct 2026 | A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma | |
| Phase 1/2Recruiting | 30 Jun 2027 | A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026